Advanced in Pure Red Cell Aplasia

Dr. Larry D. Cripe

Hematology Oncology | Hematology | Palliative Medicine
Iu Health Medical Group LLC
1701 N Senate Ave, 
Indianapolis, IN 
Accepting New Patients
Offers Telehealth
Advanced in Pure Red Cell Aplasia
Iu Health Medical Group LLC
1701 N Senate Ave, 
Indianapolis, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Larry Cripe is a Hematologist Oncology specialist and a Hematologist in Indianapolis, Indiana. Dr. Cripe is rated as an Advanced provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Childhood Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration. Dr. Cripe is currently accepting new patients.

His clinical research consists of co-authoring 53 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Palliative Medicine
Licenses
Internal Medicine in IN
Hospital Affiliations
Indiana University Health Bloomington Hospital
Indiana University Health
Indiana University Health North Hospital
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

IU HEALTH MEDICAL GROUP LLC
1701 N Senate Ave, Indianapolis, IN 46202
Other Locations
UNIVERSITY MEDICAL DIAGNOSTIC ASSOCIATES INC
550 N University Blvd, Indianapolis, IN 46202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drugs: Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Study Phase: Phase 3
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cytarabine, Daunorubicin, Uproleselan
Study Phase: Phase 2/Phase 3
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2025
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
Enrollment Status: Completed
Publish Date: January 16, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Azacitidine, Cytarabine, Decitabine, Midostaurin, Nivolumab
Study Phase: Phase 2/Phase 3
View 3 Less Clinical Trials

53 Total Publications

Correction: Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.
Correction: Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.
Journal: Bone marrow transplantation
Published: July 18, 2024
Similar Doctors
Advanced in Pure Red Cell Aplasia
Dr. Lalitha V. Nayak
Hematology | Hematology Oncology | Oncology
Advanced in Pure Red Cell Aplasia
Dr. Lalitha V. Nayak
Hematology | Hematology Oncology | Oncology

University Medical Diagnostic Associates Inc

705 Riley Hospital Dr, 
Indianapolis, IN 
 (1.3 miles away)
317-944-2066
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Lalitha Nayak is a Hematologist and a Hematologist Oncology provider in Indianapolis, Indiana. Dr. Nayak is rated as an Advanced provider by MediFind in the treatment of Pure Red Cell Aplasia. Her top areas of expertise are Mesenteric Venous Thrombosis, Sickle Cell Disease, Hemophilia A, Aplastic Anemia, and Bone Marrow Aspiration. Dr. Nayak is currently accepting new patients.

Advanced in Pure Red Cell Aplasia
Dr. Jill B. Cole
Hematology Oncology | Oncology | Hematology
Advanced in Pure Red Cell Aplasia
Dr. Jill B. Cole
Hematology Oncology | Oncology | Hematology

Major Multispecialty Associates

2455 Intelliplex Dr, 
Shelbyville, IN 
 (25.7 miles away)
317-421-1800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jill Cole is a Hematologist Oncology specialist and an Oncologist in Shelbyville, Indiana. Dr. Cole is rated as a Distinguished provider by MediFind in the treatment of Pure Red Cell Aplasia. Her top areas of expertise are WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Pleuropulmonary Blastoma, and Lung Cancer. Dr. Cole is currently accepting new patients.

Advanced in Pure Red Cell Aplasia
Dr. Patrick J. Loehrer
Hematology Oncology | Oncology
Advanced in Pure Red Cell Aplasia
Dr. Patrick J. Loehrer
Hematology Oncology | Oncology

University Medical Diagnostic Associates Inc

550 N University Blvd, 
Indianapolis, IN 
 (1.3 miles away)
217-274-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Loehrer is a Hematologist Oncology specialist and an Oncologist in Indianapolis, Indiana. Dr. Loehrer is rated as an Elite provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Thymic Epithelial Tumor, Colorectal Cancer, Pancreatic Cancer, Pancreaticoduodenectomy, and Thymectomy. Dr. Loehrer is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cripe's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 28 Advanced Conditions
View All 41 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile